Current Management of Hepatocellular Carcinoma

Medical Clinics of North America

Volumn 93, Issue 4, 2009, Pages 885-900

  Mendizabal, Manuel ^a   Reddy, K Rajender ^b  

^a UNIVERSIDAD AUSTRAL   (Argentina)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Hepatocellular carcinoma; Liver; Liver transplantation; Sorafenib

Indexed keywords

ALCOHOL; ALPHA FETOPROTEIN; ANTINEOPLASTIC AGENT; BEVACIZUMAB; CETUXIMAB; CISPLATIN; DOXORUBICIN; ERLOTINIB; IODINATED POPPYSEED OIL; SORAFENIB;

ADVANCED CANCER; ALGORITHM; ALOPECIA; BONE MARROW DEPRESSION; BREAST CANCER; CANCER DIAGNOSIS; CANCER STAGING; CANCER SURVIVAL; CHEMOEMBOLIZATION; CHOLECYSTITIS; CLINICAL TRIAL; CRYOSURGERY; ECHOGRAPHY; HIGH RISK POPULATION; HUMAN; INVASIVE CARCINOMA; ISCHEMIA; ISCHEMIC CHOLECYSTITIS; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER METASTASIS; LIVER RESECTION; LIVER TRANSPLANTATION; LUNG CANCER; METASTASIS; MULTIPLE CYCLE TREATMENT; NAUSEA; NONHUMAN; PRIORITY JOURNAL; RADIOFREQUENCY ABLATION; REVIEW; VOMITING;

ALGORITHMS; BENZENESULFONATES; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; CHEMOEMBOLIZATION, THERAPEUTIC; DISEASE PROGRESSION; HEPATECTOMY; HEPATITIS B; HEPATITIS C; HUMANS; LIVER; LIVER NEOPLASMS; LIVER TRANSPLANTATION; MAGNETIC RESONANCE IMAGING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PYRIDINES; TOMOGRAPHY, X-RAY COMPUTED; TREATMENT OUTCOME;

EID: 67649408820     PISSN: 00257125     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mcna.2009.03.004     Document Type: Review

References (97)

1. Parkin D.M., Bray F., Ferlay J., et al. Global cancer statistics, 2002. CA Cancer J Clin 55 2 (2005) 74-108
2. Bolondi L., Sofia S., Siringo S., et al. Surveillance programme of cirrhotic patients for early diagnosis and treatment of hepatocellular carcinoma: a cost effectiveness analysis. Gut 48 2 (2001) 251-259
3. El-Serag H.B., and Rudolph K.L. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology 132 7 (2007) 2557-2576
4. El-Serag H.B., Davila J.A., Petersen N.J., et al. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 10 (2003) 817-823
5. Colombo M., de Franchis R., Del Ninno E., et al. Hepatocellular carcinoma in Italian patients with cirrhosis. N Engl J Med 325 10 (1991) 675-680
6. Velazquez R.F., Rodriguez M., Navascues C.A., et al. Prospective analysis of risk factors for hepatocellular carcinoma in patients with liver cirrhosis. Hepatology 37 3 (2003) 520-527
7. Bruix J., Sherman M., Llovet J.M., et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 3 (2001) 421-430
8. Oka H., Kurioka N., Kim K., et al. Prospective study of early detection of hepatocellular carcinoma in patients with cirrhosis. Hepatology 12 4 Pt 1 (1990) 680-687
9. Wong L.L., Limm W.M., Severino R., et al. Improved survival with screening for hepatocellular carcinoma. Liver Transpl 6 3 (2000) 320-325
10. Llovet J.M., and Bruix J. Novel advancements in the management of hepatocellular carcinoma in 2008. J Hepatol 48 Suppl 1 (2008) S20-S37
11. Zhang B.H., Yang B.H., and Tang Z.Y. Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol 130 7 (2004) 417-422
12. Trevisani F., D'Intino P.E., Morselli-Labate A.M., et al. Serum alpha-fetoprotein for diagnosis of hepatocellular carcinoma in patients with chronic liver disease: influence of HBsAg and anti-HCV status. J Hepatol 34 4 (2001) 570-575
13. Sherman M. Alphafetoprotein: an obituary. J Hepatol 34 4 (2001) 603-605
14. Zoli M., Magalotti D., Bianchi G., et al. Efficacy of a surveillance program for early detection of hepatocellular carcinoma. Cancer 78 5 (1996) 977-985
15. Durazo F.A., Blatt L.M., Corey W.G., et al. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma. J Gastroenterol Hepatol 23 10 (2008) 1541-1548
16. Sterling R.K., Jeffers L., Gordon F., et al. Clinical utility of AFP-L3% measurement in North American patients with HCV-related cirrhosis. Am J Gastroenterol 102 10 (2007) 2196-2205
17. Sterling R.K., Jeffers L., Gordon F., et al. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma. Clin Gastroenterol Hepatol 7 1 (2009) 104-113
18. Oka H., Saito A., Ito K., et al. Multicenter prospective analysis of newly diagnosed hepatocellular carcinoma with respect to the percentage of lens culinaris agglutinin-reactive alpha-fetoprotein. J Gastroenterol Hepatol 16 12 (2001) 1378-1383
19. Taketa K., Endo Y., Sekiya C., et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoproteins in early detection of hepatocellular carcinoma. Cancer Res 53 22 (1993) 5419-5423
20. Khien V.V., Mao H.V., Chinh T.T., et al. Clinical evaluation of lentil lectin-reactive alpha-fetoprotein-L3 in histology-proven hepatocellular carcinoma. Int J Biol Markers 16 2 (2001) 105-111
21. Chen T.H., Chen C.J., Yen M.F., et al. Ultrasound screening and risk factors for death from hepatocellular carcinoma in a high risk group in Taiwan. Int J Cancer 98 2 (2002) 257-261
22. Kim C.K., Lim J.H., and Lee W.J. Detection of hepatocellular carcinomas and dysplastic nodules in cirrhotic liver: accuracy of ultrasonography in transplant patients. J Ultrasound Med 20 2 (2001) 99-104
23. Bruix J., and Sherman M. Management of hepatocellular carcinoma. Hepatology 42 5 (2005) 1208-1236
24. Zhang B., and Yang B. Combined alpha fetoprotein testing and ultrasonography as a screening test for primary liver cancer. J Med Screen 6 2 (1999) 108-110
25. Arguedas M.R., Chen V.K., Eloubeidi M.A., et al. Screening for hepatocellular carcinoma in patients with hepatitis C cirrhosis: a cost-utility analysis. Am J Gastroenterol 98 3 (2003) 679-690
26. Choi D., Kim S.H., Lim J.H., et al. Detection of hepatocellular carcinoma: combined T2-weighted and dynamic gadolinium-enhanced MRI versus combined CT during arterial portography and CT hepatic arteriography. J Comput Assist Tomogr 25 5 (2001) 777-785
27. Hayashi M., Matsui O., Ueda K., et al. Progression to hypervascular hepatocellular carcinoma: correlation with intranodular blood supply evaluated with CT during intraarterial injection of contrast material. Radiology 225 1 (2002) 143-149
28. El-Serag H.B., Marrero J.A., Rudolph L., et al. Diagnosis and treatment of hepatocellular carcinoma. Gastroenterology 134 6 (2008) 1752-1763
29. Burrel M., Llovet J.M., Ayuso C., et al. MRI angiography is superior to helical CT for detection of HCC prior to liver transplantation: an explant correlation. Hepatology 38 4 (2003) 1034-1042
30. Libbrecht L., Bielen D., Verslype C., et al. Focal lesions in cirrhotic explant livers: pathological evaluation and accuracy of pretransplantation imaging examinations. Liver Transpl 8 9 (2002) 749-761
31. Rode A., Bancel B., Douek P., et al. Small nodule detection in cirrhotic livers: evaluation with US, spiral CT, and MRI and correlation with pathologic examination of explanted liver. J Comput Assist Tomogr 25 3 (2001) 327-336
32. Ebara M., Ohto M., Watanabe Y., et al. Diagnosis of small hepatocellular carcinoma: correlation of MR imaging and tumor histologic studies. Radiology 159 2 (1986) 371-377
33. Byrnes V., Shi H., Kiryu S., et al. The clinical outcome of small (<20 mm) arterially enhancing nodules on MRI in the cirrhotic liver. Am J Gastroenterol 102 8 (2007) 1654-1659
34. A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology 28 3 (1998) 751-755
35. Kudo M., Chung H., and Osaki Y. Prognostic staging system for hepatocellular carcinoma (CLIP score): its value and limitations, and a proposal for a new staging system, the Japan integrated staging score (JIS score). J Gastroenterol 38 3 (2003) 207-215
36. Llovet J.M., Bru C., and Bruix J. Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis 19 3 (1999) 329-338
37. Okuda K., Ohtsuki T., Obata H., et al. Natural history of hepatocellular carcinoma and prognosis in relation to treatment. Study of 850 patients. Cancer 56 4 (1985) 918-928
38. Marrero J.A., Fontana R.J., Barrat A., et al. Prognosis of hepatocellular carcinoma: comparison of 7 staging systems in an American cohort. Hepatology 41 4 (2005) 707-716
39. Sakamoto M., and Hirohashi S. Natural history and prognosis of adenomatous hyperplasia and early hepatocellular carcinoma: multi-institutional analysis of 53 nodules followed up for more than 6 months and 141 patients with single early hepatocellular carcinoma treated by surgical resection or percutaneous ethanol injection. Jpn J Clin Oncol 28 10 (1998) 604-608
40. Takayama T., Makuuchi M., Hirohashi S., et al. Early hepatocellular carcinoma as an entity with a high rate of surgical cure. Hepatology 28 5 (1998) 1241-1246
41. Imamura H., Matsuyama Y., Tanaka E., et al. Risk factors contributing to early and late phase intrahepatic recurrence of hepatocellular carcinoma after hepatectomy. J Hepatol 38 2 (2003) 200-207
42. Okada S., Shimada K., Yamamoto J., et al. Predictive factors for postoperative recurrence of hepatocellular carcinoma. Gastroenterology 106 6 (1994) 1618-1624
43. Poon R.T., Fan S.T., Lo C.M., et al. Intrahepatic recurrence after curative resection of hepatocellular carcinoma: long-term results of treatment and prognostic factors. Ann Surg 229 2 (1999) 216-222
44. Ikai I., Arii S., Kojiro M., et al. Reevaluation of prognostic factors for survival after liver resection in patients with hepatocellular carcinoma in a Japanese nationwide survey. Cancer 101 4 (2004) 796-802
45. Llovet J.M., Fuster J., and Bruix J. Intention-to-treat analysis of surgical treatment for early hepatocellular carcinoma: resection versus transplantation. Hepatology 30 6 (1999) 1434-1440
46. Vauthey J.N., Lauwers G.Y., Esnaola N.F., et al. Simplified staging for hepatocellular carcinoma. J Clin Oncol 20 6 (2002) 1527-1536
47. Mazzaferro V., Romito R., Schiavo M., et al. Prevention of hepatocellular carcinoma recurrence with alpha-interferon after liver resection in HCV cirrhosis. Hepatology 44 6 (2006) 1543-1554
48. Sun H.C., Tang Z.Y., Wang L., et al. Postoperative interferon alpha treatment postponed recurrence and improved overall survival in patients after curative resection of HBV-related hepatocellular carcinoma: a randomized clinical trial. J Cancer Res Clin Oncol 132 7 (2006) 458-465
49. Lo C.M., Liu C.L., Chan S.C., et al. A randomized, controlled trial of postoperative adjuvant interferon therapy after resection of hepatocellular carcinoma. Ann Surg 245 6 (2007) 831-842
50. Schwartz J.D., Schwartz M., Mandeli J., et al. Neoadjuvant and adjuvant therapy for resectable hepatocellular carcinoma: review of the randomised clinical trials. Lancet Oncol 3 10 (2002) 593-603
51. Yamasaki S., Hasegawa H., Kinoshita H., et al. A prospective randomized trial of the preventive effect of pre-operative transcatheter arterial embolization against recurrence of hepatocellular carcinoma. Jpn J Cancer Res 87 2 (1996) 206-211
52. Torzilli G., Olivari N., Moroni E., et al. Contrast-enhanced intraoperative ultrasonography in surgery for hepatocellular carcinoma in cirrhosis. Liver Transpl 10 2 Suppl 1 (2004) S34-S38
53. Ringe B., Pichlmayr R., Wittekind C., et al. Surgical treatment of hepatocellular carcinoma: experience with liver resection and transplantation in 198 patients. World J Surg 15 2 (1991) 270-285
54. Bismuth H., Chiche L., Adam R., et al. Liver resection versus transplantation for hepatocellular carcinoma in cirrhotic patients. Ann Surg 218 2 (1993) 145-151
55. Moreno P., Jaurrieta E., Figueras J., et al. Orthotopic liver transplantation: treatment of choice in cirrhotic patients with hepatocellular carcinoma?. Transplant Proc 27 4 (1995) 2296-2298
56. Mazzaferro V., Regalia E., Doci R., et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med 334 11 (1996) 693-699
57. Yao F.Y., Ferrell L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: expansion of the tumor size limits does not adversely impact survival. Hepatology 33 6 (2001) 1394-1403
58. Yao F.Y., Xiao L., Bass N.M., et al. Liver transplantation for hepatocellular carcinoma: validation of the UCSF-expanded criteria based on preoperative imaging. Am J Transplant 7 11 (2007) 2587-2596
59. Yao F.Y. Liver transplantation for hepatocellular carcinoma: beyond the Milan criteria. Am J Transplant 8 10 (2008) 1982-1989
60. Yao F.Y., Hirose R., LaBerge J.M., et al. A prospective study on downstaging of hepatocellular carcinoma prior to liver transplantation. Liver Transpl 11 12 (2005) 1505-1514
61. Ravaioli M., Grazi G.L., Piscaglia F., et al. Liver transplantation for hepatocellular carcinoma: results of down-staging in patients initially outside the Milan selection criteria. Am J Transplant 8 12 (2008) 2547-2557
62. Yao F.Y., Kerlan Jr. R.K., Hirose R., et al. Excellent outcome following down-staging of hepatocellular carcinoma prior to liver transplantation: an intention-to-treat analysis. Hepatology 48 3 (2008) 819-827
63. Yao F.Y. Expanded criteria for hepatocellular carcinoma: down-staging with a view to liver transplantation-yes. Semin Liver Dis 26 3 (2006) 239-247
64. Graziadei I.W., Sandmueller H., Waldenberger P., et al. Chemoembolization followed by liver transplantation for hepatocellular carcinoma impedes tumor progression while on the waiting list and leads to excellent outcome. Liver Transpl 9 6 (2003) 557-563
65. Yao F.Y., Bass N.M., Nikolai B., et al. Liver transplantation for hepatocellular carcinoma: analysis of survival according to the intention-to-treat principle and dropout from the waiting list. Liver Transpl 8 10 (2002) 873-883
66. Trotter J.F., Wachs M., Everson G.T., et al. Adult-to-adult transplantation of the right hepatic lobe from a living donor. N Engl J Med 346 14 (2002) 1074-1082
67. Gondolesi G.E., Roayaie S., Munoz L., et al. Adult living donor liver transplantation for patients with hepatocellular carcinoma: extending UNOS priority criteria. Ann Surg 239 2 (2004) 142-149
68. Kaihara S., Kiuchi T., Ueda M., et al. Living-donor liver transplantation for hepatocellular carcinoma. Transplantation 75 3 Suppl (2003) S37-S40
69. Todo S., and Furukawa H. Living donor liver transplantation for adult patients with hepatocellular carcinoma: experience in Japan. Ann Surg 240 3 (2004) 451-459 [discussion: 459-61]
70. Fisher R.A., Kulik L.M., Freise C.E., et al. Hepatocellular carcinoma recurrence and death following living and deceased donor liver transplantation. Am J Transplant 7 6 (2007) 1601-1608
71. Ishii H., Okada S., Nose H., et al. Local recurrence of hepatocellular carcinoma after percutaneous ethanol injection. Cancer 77 9 (1996) 1792-1796
72. Livraghi T., Giorgio A., Marin G., et al. Hepatocellular carcinoma and cirrhosis in 746 patients: long-term results of percutaneous ethanol injection. Radiology 197 1 (1995) 101-108
73. Ebara M., Okabe S., Kita K., et al. Percutaneous ethanol injection for small hepatocellular carcinoma: therapeutic efficacy based on 20-year observation. J Hepatol 43 3 (2005) 458-464
74. Lencioni R.A., Allgaier H.P., Cioni D., et al. Small hepatocellular carcinoma in cirrhosis: randomized comparison of radio-frequency thermal ablation versus percutaneous ethanol injection. Radiology 228 1 (2003) 235-240
75. Lin S.M., Lin C.J., Lin C.C., et al. Radiofrequency ablation improves prognosis compared with ethanol injection for hepatocellular carcinoma ≤4 cm. Gastroenterology 127 6 (2004) 1714-1723
76. Livraghi T., Goldberg S.N., Lazzaroni S., et al. Small hepatocellular carcinoma: treatment with radio-frequency ablation versus ethanol injection. Radiology 210 3 (1999) 655-661
77. Shiina S., Teratani T., Obi S., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 1 (2005) 122-130
78. Lin S.M., Lin C.J., Lin C.C., et al. Randomised controlled trial comparing percutaneous radiofrequency thermal ablation, percutaneous ethanol injection, and percutaneous acetic acid injection to treat hepatocellular carcinoma of 3 cm or less. Gut 54 8 (2005) 1151-1156
79. Brunello F., Veltri A., Carucci P., et al. Radiofrequency ablation versus ethanol injection for early hepatocellular carcinoma: a randomized controlled trial. Scand J Gastroenterol 43 6 (2008) 727-735
80. Teratani T., Yoshida H., Shiina S., et al. Radiofrequency ablation for hepatocellular carcinoma in so-called high-risk locations. Hepatology 43 5 (2006) 1101-1108
81. Llovet J.M., Vilana R., Bru C., et al. Increased risk of tumor seeding after percutaneous radiofrequency ablation for single hepatocellular carcinoma. Hepatology 33 5 (2001) 1124-1129
82. Chen M.S., Li J.Q., Zheng Y., et al. A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg 243 3 (2006) 321-328
83. Huang G.T., Lee P.H., Tsang Y.M., et al. Percutaneous ethanol injection versus surgical resection for the treatment of small hepatocellular carcinoma: a prospective study. Ann Surg 242 1 (2005) 36-42
84. Hasegawa K., Makuuchi M., Takayama T., et al. Surgical resection vs percutaneous ablation for hepatocellular carcinoma: a preliminary report of the Japanese nationwide survey. J Hepatol 49 4 (2008) 589-594
85. Schwarz R.E., and Smith D.D. Trends in local therapy for hepatocellular carcinoma and survival outcomes in the US population. Am J Surg 195 6 (2008) 829-836
86. Llovet J.M., and Bruix J. Systematic review of randomized trials for unresectable hepatocellular carcinoma: chemoembolization improves survival. Hepatology 37 2 (2003) 429-442
87. Marelli L., Stigliano R., Triantos C., et al. Transarterial therapy for hepatocellular carcinoma: which technique is more effective? A systematic review of cohort and randomized studies. Cardiovasc Intervent Radiol 30 1 (2007) 6-25
88. Takayasu K., Arii S., Ikai I., et al. Prospective cohort study of transarterial chemoembolization for unresectable hepatocellular carcinoma in 8510 patients. Gastroenterology 131 2 (2006) 461-469
89. Jaeger H.J., Mehring U.M., Castaneda F., et al. Sequential transarterial chemoembolization for unresectable advanced hepatocellular carcinoma. Cardiovasc Intervent Radiol 19 6 (1996) 388-396
90. Molinari M., Kachura J.R., Dixon E., et al. Transarterial chemoembolisation for advanced hepatocellular carcinoma: results from a North American Cancer Centre. Clin Oncol (R Coll Radiol) 18 9 (2006) 684-692
91. Castells A., Bruix J., Ayuso C., et al. Transarterial embolization for hepatocellular carcinoma. Antibiotic prophylaxis and clinical meaning of postembolization fever. J Hepatol 22 4 (1995) 410-415
92. Lopez P.M., Villanueva A., and Llovet J.M. Systematic review: evidence-based management of hepatocellular carcinoma-an updated analysis of randomized controlled trials. Aliment Pharmacol Ther 23 11 (2006) 1535-1547
93. Zhu A.X. Systemic therapy of advanced hepatocellular carcinoma: how hopeful should we be?. Oncologist 11 7 (2006) 790-800
94. Llovet J.M., and Bruix J. Molecular targeted therapies in hepatocellular carcinoma. Hepatology 48 4 (2008) 1312-1327
95. Roberts L.R. Sorafenib in liver cancer-just the beginning. N Engl J Med 359 4 (2008) 420-422
96. Chang Y.S., Adnane J., Trail P.A., et al. Sorafenib (BAY 43-9006) inhibits tumor growth and vascularization and induces tumor apoptosis and hypoxia in RCC xenograft models. Cancer Chemother Pharmacol 59 5 (2007) 561-574
97. Llovet J.M., Ricci S., Mazzaferro V., et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 4 (2008) 378-390